Mr. Allen Davidoff reports

XORTX ANNOUNCES RESULTS OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS

XORTX Therapeutics Inc. has released the results of its annual and special meeting of shareholders, held Tuesday, March 24, 2026.

A total of 2,407,148 common shares of the company were represented at the meeting, representing approximately 35 per cent of the total number of common shares of the company issued and outstanding. All matters presented for approval at the meeting were duly authorized and approved, including the election of all five management nominees (Anthony Giovinazzo (chair), Allen Davidoff (chief executive officer), Mika Grasso, Richard Grieve and George Scorsis) to the board of directors of the company, the appointment of Davidson & Company LLP as the auditor of the company for the ensuing year and the authorization of the directors to fix its remuneration, the reapproval of the stock option plan, and the approval of the share consolidation. Detailed results are available in the report of voting results filed on the company's SEDAR+ profile.

About XORTX Therapeutics Inc.

XORTX is a pharmaceutical company with three clinically advanced products in development: (1) its lead program XRx-026 program for the treatment of gout; (2) XRx-008 program for ADPKD; and (3) XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the company is developing XRx-225, a preclinical-stage program for Type 2 diabetic nephropathy. XORTX is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. XORTX is dedicated to developing medications that improve the quality of life and health of individuals with gout and other important diseases.

We seek Safe Harbor.